Omeros jumps after BLA submission for respiratory med

• Omeros shares climb 7.5% after the company completes its rolling submission of its Biologics License Application to the FDA for narsoplimab for the treatment of a complication associated with stem cell transplantation.
• The company has requested priority review for the BLA, and applicable regulations provide FDA up to 60 days to determine the filing and review designation for the application.
• If the stock's advance stays at that level, it will be Omeros's largest rise since Aug. 10, when it reported positive results from a compassionate use study evaluating narsoplimab in severely ill COVID-19 patients with acute respiratory distress syndrome requiring mechanical ventilation.
• The BLA is for the use of narsoplimab in treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). 
• Narsoplimab targets mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of complement, and has received breakthrough therapy designation and orphan drug designation from FDA for HSCT-TMA.
• https://seekingalpha.com/news/3637588-omeros-jumps-7_5-after-completing-bla-submission-for-narsoplimab